October 2024 - Cancer Currents Blog
-
Delivering Palliative Care by Telehealth Meets the Needs of People with CancerIn a study of people with advanced lung cancer, palliative care delivered via telehealth was just as effective at improving patients’ quality of life and other measures of well-being as care delivered in person.
-
Program Connects Adolescents and Young Adults to Quality Cancer CareA 10-year-old program at an NCI-Designated Cancer Center has had substantial success at increasing the number of adolescents and young adults with cancer who get recommended treatment and services, including greater clinical trial participation and use of fertility services.
-
Will Ponsegromab Be a Game Changer for Cancer Cachexia?In a clinical trial, people with advanced cancer and cachexia treated with the experimental drug ponsegromab gained an average of 2 to 6 pounds over 12 weeks, depending on the dose they received. Participants treated with the placebo lost an average of 1 pound over the same time period.
-
As More People with Cancer Use Medical Cannabis, Oncologists Face Questions They Struggle to AnswerUp to 40% of people being treated for cancer use cannabis to help with side effects like pain and anxiety. But with evidence from studies on cannabis lacking, clinicians feel ill-equipped to answer patient questions about its safety and effectiveness.
-
Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In?FDA recently approved the Shield test, the first blood test for the primary screening of people at average risk of colorectal cancer. Where does it fit in with other screening options for the disease, including colonoscopy and stool tests?
-
Some Women Avoid Breast Cancer Screening After False-Positive Mammogram ResultsSome women who receive a false-positive result on a mammogram may not come back for routine breast cancer screening in the future, a new study finds. Better doctor–patient communication about the screening process is needed, several researchers said.
-
Combination Chemo Helps People with Leiomyosarcoma Live LongerResults from a French clinical trial have identified what experts say should now be the recommended initial treatment of advanced leiomyosarcoma. In the trial, the combination of trabectedin (Yondelis) and doxorubicin improved survival by a median of 9 months.